Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.16 USD
+0.05 (2.37%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.16 USD
+0.05 (2.37%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Zacks News
Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment
by Zacks Equity Research
Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.
Is Caribou Biosciences (CRBU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Caribou Biosciences, Inc. (CRBU) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.
How Much Upside is Left in Caribou Biosciences, Inc. (CRBU)? Wall Street Analysts Think 316.72%
by Zacks Equity Research
The mean of analysts' price targets for Caribou Biosciences, Inc. (CRBU) points to a 316.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer
by Zacks Equity Research
Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.
Caribou Biosciences, Inc. (CRBU) Surges 45.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Caribou Biosciences, Inc. (CRBU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 4.17% and 2.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 6.38% and 2.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 8.33% and 8.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of -24.32% and 48.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Morphic Holding, Inc. (MORF) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 183.95% and 1,317.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Incyte (INCY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Legend Biotech Corporation Sponsored ADR (LEGN) Soars 10.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.